1034 related articles for article (PubMed ID: 27151177)
1. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
2. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
Loomba R; Sirlin CB; Ang B; Bettencourt R; Jain R; Salotti J; Soaft L; Hooker J; Kono Y; Bhatt A; Hernandez L; Nguyen P; Noureddin M; Haufe W; Hooker C; Yin M; Ehman R; Lin GY; Valasek MA; Brenner DA; Richards L;
Hepatology; 2015 Apr; 61(4):1239-50. PubMed ID: 25482832
[TBL] [Abstract][Full Text] [Related]
3. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
Joy TR; McKenzie CA; Tirona RG; Summers K; Seney S; Chakrabarti S; Malhotra N; Beaton MD
World J Gastroenterol; 2017 Jan; 23(1):141-150. PubMed ID: 28104990
[TBL] [Abstract][Full Text] [Related]
6. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.
Idilman IS; Keskin O; Celik A; Savas B; Elhan AH; Idilman R; Karcaaltincaba M
Acta Radiol; 2016 Mar; 57(3):271-8. PubMed ID: 25855666
[TBL] [Abstract][Full Text] [Related]
7. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
[TBL] [Abstract][Full Text] [Related]
8. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.
Le TA; Chen J; Changchien C; Peterson MR; Kono Y; Patton H; Cohen BL; Brenner D; Sirlin C; Loomba R;
Hepatology; 2012 Sep; 56(3):922-32. PubMed ID: 22431131
[TBL] [Abstract][Full Text] [Related]
9. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
[TBL] [Abstract][Full Text] [Related]
10. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.
Noureddin M; Lam J; Peterson MR; Middleton M; Hamilton G; Le TA; Bettencourt R; Changchien C; Brenner DA; Sirlin C; Loomba R
Hepatology; 2013 Dec; 58(6):1930-40. PubMed ID: 23696515
[TBL] [Abstract][Full Text] [Related]
11. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
[TBL] [Abstract][Full Text] [Related]
12. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
[TBL] [Abstract][Full Text] [Related]
14. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
15. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
[TBL] [Abstract][Full Text] [Related]
16. Assessment of a high-SNR chemical-shift-encoded MRI with complex reconstruction for proton density fat fraction (PDFF) estimation overall and in the low-fat range.
Park CC; Hooker C; Hooker JC; Bass E; Haufe W; Schlein A; Covarrubias Y; Heba E; Bydder M; Wolfson T; Gamst A; Loomba R; Schwimmer J; Hernando D; Reeder SB; Middleton M; Sirlin CB; Hamilton G
J Magn Reson Imaging; 2019 Jan; 49(1):229-238. PubMed ID: 29707848
[TBL] [Abstract][Full Text] [Related]
17. Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease.
Choi SJ; Kim SM; Kim YS; Kwon OS; Shin SK; Kim KK; Lee K; Park IB; Choi CS; Chung DH; Jung J; Paek M; Lee DH
Diabetes Metab J; 2021 Sep; 45(5):739-752. PubMed ID: 33108854
[TBL] [Abstract][Full Text] [Related]
18. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.
Lin SC; Heba E; Bettencourt R; Lin GY; Valasek MA; Lunde O; Hamilton G; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2017 Mar; 45(6):844-854. PubMed ID: 28116801
[TBL] [Abstract][Full Text] [Related]
19. Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis.
Chen J; Allen AM; Therneau TM; Chen J; Li J; Hoodeshenas S; Chen J; Lu X; Zhu Z; Venkatesh SK; Song B; Ehman RL; Yin M
Eur Radiol; 2022 Feb; 32(2):950-958. PubMed ID: 34432123
[TBL] [Abstract][Full Text] [Related]
20. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
